[
  {
    "ts": null,
    "headline": "Equities Mostly Rise Intraday Amid Amazon Boost as Markets Await Week's Key Earnings",
    "summary": "US benchmark equity indexes were mostly higher after midday Monday amid a jump in Amazon.com (AMZN)",
    "url": "https://finnhub.io/api/news?id=6b710a8664ba9129bb9d27ae0ca2758fbe49832385b4441ab07935200b23531c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762196940,
      "headline": "Equities Mostly Rise Intraday Amid Amazon Boost as Markets Await Week's Key Earnings",
      "id": 137305838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "US benchmark equity indexes were mostly higher after midday Monday amid a jump in Amazon.com (AMZN)",
      "url": "https://finnhub.io/api/news?id=6b710a8664ba9129bb9d27ae0ca2758fbe49832385b4441ab07935200b23531c"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline in Afternoon Trading",
    "summary": "Health care stocks declined Monday afternoon, with the NYSE Health Care Index shedding 0.3% and the",
    "url": "https://finnhub.io/api/news?id=aab7fea18382a07dab9a8f7d105772cf9077b0c74e567b739ef9d678e3013dd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762196373,
      "headline": "Sector Update: Health Care Stocks Decline in Afternoon Trading",
      "id": 137306009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks declined Monday afternoon, with the NYSE Health Care Index shedding 0.3% and the",
      "url": "https://finnhub.io/api/news?id=aab7fea18382a07dab9a8f7d105772cf9077b0c74e567b739ef9d678e3013dd0"
    }
  },
  {
    "ts": null,
    "headline": "Did Novo Nordisk Just Say \"Checkmate\" to Pfizer?",
    "summary": "These two leading drugmakers are fighting over a promising GLP-1 candidate.",
    "url": "https://finnhub.io/api/news?id=342f130e8639eddd82f904dfe09bc07dc85bafbba8668e2f365c627450ca986c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762194180,
      "headline": "Did Novo Nordisk Just Say \"Checkmate\" to Pfizer?",
      "id": 137306010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These two leading drugmakers are fighting over a promising GLP-1 candidate.",
      "url": "https://finnhub.io/api/news?id=342f130e8639eddd82f904dfe09bc07dc85bafbba8668e2f365c627450ca986c"
    }
  },
  {
    "ts": null,
    "headline": "Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo",
    "summary": "Metsera called Pfizer's claims \"nonsense\" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.",
    "url": "https://finnhub.io/api/news?id=eb0b68fc0393e4683d48117c1a1db477824f90f73bbead9a335bad823f104353",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762191745,
      "headline": "Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo",
      "id": 137306011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera called Pfizer's claims \"nonsense\" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=eb0b68fc0393e4683d48117c1a1db477824f90f73bbead9a335bad823f104353"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera",
    "summary": "Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.",
    "url": "https://finnhub.io/api/news?id=4e6bdbbf93a3d68ed6b5b4754da56f56eccf688e67afbec935e71ad511a1bb8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762189380,
      "headline": "Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera",
      "id": 137305915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.",
      "url": "https://finnhub.io/api/news?id=4e6bdbbf93a3d68ed6b5b4754da56f56eccf688e67afbec935e71ad511a1bb8d"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
    "summary": "The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
    "url": "https://finnhub.io/api/news?id=a429253b496cde4c47322c94baccf233d35054885dd8c42a65b7c8c3e6e2a47f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762186400,
      "headline": "Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
      "id": 137302924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
      "url": "https://finnhub.io/api/news?id=a429253b496cde4c47322c94baccf233d35054885dd8c42a65b7c8c3e6e2a47f"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Pfizer: “We’ll Find Out if Pfizer’s Going to Be More of a Stock and Less of a Bond Equivalent”",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer had in this week’s game plan. Cramer discussed the future possibilities of the stock, as he commented: “Now, will Pfizer break out from the $25 level? Oh, it’s been a dull run for this former growth drug stock as shareholders seem to be satisfied with […]",
    "url": "https://finnhub.io/api/news?id=6c6e728da83422bb8c0c09676e29f0949a5b8cb86be7b0e44676173f40b9bd66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762186001,
      "headline": "Jim Cramer on Pfizer: “We’ll Find Out if Pfizer’s Going to Be More of a Stock and Less of a Bond Equivalent”",
      "id": 137303016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer had in this week’s game plan. Cramer discussed the future possibilities of the stock, as he commented: “Now, will Pfizer break out from the $25 level? Oh, it’s been a dull run for this former growth drug stock as shareholders seem to be satisfied with […]",
      "url": "https://finnhub.io/api/news?id=6c6e728da83422bb8c0c09676e29f0949a5b8cb86be7b0e44676173f40b9bd66"
    }
  },
  {
    "ts": null,
    "headline": "Metsera Issues Statement in Response to Litigation",
    "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to litigation filed against the Company by Pfizer:",
    "url": "https://finnhub.io/api/news?id=1997095610b13d3fffc62f1191acdb1b8fed388b6b2d4816b99c3f9d321642f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762185720,
      "headline": "Metsera Issues Statement in Response to Litigation",
      "id": 137303017,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to litigation filed against the Company by Pfizer:",
      "url": "https://finnhub.io/api/news?id=1997095610b13d3fffc62f1191acdb1b8fed388b6b2d4816b99c3f9d321642f3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera deal",
    "summary": "Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera, redoubling its fight to stop Novo’s bid for the biotech...",
    "url": "https://finnhub.io/api/news?id=af72f8e126bac0e32140f9b369ed9de0a37c0e1fffa1693beef6b543559a2e7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762185448,
      "headline": "Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera deal",
      "id": 137303018,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera, redoubling its fight to stop Novo’s bid for the biotech...",
      "url": "https://finnhub.io/api/news?id=af72f8e126bac0e32140f9b369ed9de0a37c0e1fffa1693beef6b543559a2e7f"
    }
  },
  {
    "ts": null,
    "headline": "Update: Pfizer Sues Metsera, Novo Nordisk Over Alleged Breach of Merger Agreement",
    "summary": "(Updates to add comment from Novo Nordisk in the sixth paragraph.) Pfizer (PFE) said late Friday",
    "url": "https://finnhub.io/api/news?id=7620c07461549c1abdcc5f888faf744cd739c96beb4af443c50ae2977bb19ffb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762182900,
      "headline": "Update: Pfizer Sues Metsera, Novo Nordisk Over Alleged Breach of Merger Agreement",
      "id": 137303019,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Updates to add comment from Novo Nordisk in the sixth paragraph.) Pfizer (PFE) said late Friday",
      "url": "https://finnhub.io/api/news?id=7620c07461549c1abdcc5f888faf744cd739c96beb4af443c50ae2977bb19ffb"
    }
  },
  {
    "ts": null,
    "headline": "Kimberly-Clark to buy Tylenol maker Kenvue, Iren & Microsoft deal",
    "summary": "There are a number of stocks on the move on Monday, Nov. 3. Kimberly-Clark (KMB) announced it is buying Kenvue (KVUE) in a deal valued at $48.7 billion. Iren (IREN) shares are soaring after striking a $9.7 billion deal with Microsoft (MSFT). Pfizer (PFE) is suing to block Novo Nordisk's (NVO) bid for obesity startup Metsera (MTSR). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=b3234771f5ab3bf0eb287ec28c0160c94d222e499842f52ff962f7b758a874f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762180473,
      "headline": "Kimberly-Clark to buy Tylenol maker Kenvue, Iren & Microsoft deal",
      "id": 137302011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "There are a number of stocks on the move on Monday, Nov. 3. Kimberly-Clark (KMB) announced it is buying Kenvue (KVUE) in a deal valued at $48.7 billion. Iren (IREN) shares are soaring after striking a $9.7 billion deal with Microsoft (MSFT). Pfizer (PFE) is suing to block Novo Nordisk's (NVO) bid for obesity startup Metsera (MTSR). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=b3234771f5ab3bf0eb287ec28c0160c94d222e499842f52ff962f7b758a874f4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera",
    "summary": "Pfizer’s lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing off a smaller competitor.",
    "url": "https://finnhub.io/api/news?id=9ded1bb7699c279d95188563791c48385fbd15bbb3e5fae6c498777a15bb07af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762179540,
      "headline": "Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera",
      "id": 137303021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer’s lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing off a smaller competitor.",
      "url": "https://finnhub.io/api/news?id=9ded1bb7699c279d95188563791c48385fbd15bbb3e5fae6c498777a15bb07af"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Berkshire Hathaway profits rise, Beyond Meat postpones earnings, with Palantir results on deck",
    "summary": "Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=77751acd3fee695d16d7196965260c39596cdea6c6951eba1362007d485a5d79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762175191,
      "headline": "Earnings live: Berkshire Hathaway profits rise, Beyond Meat postpones earnings, with Palantir results on deck",
      "id": 137301997,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=77751acd3fee695d16d7196965260c39596cdea6c6951eba1362007d485a5d79"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk",
    "summary": "NEW YORK, November 03, 2025--Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.",
    "url": "https://finnhub.io/api/news?id=7857cf92c3127e42af7da3b65c2e174c5aaf06d5edd460d415b9bcfb0eea67d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762174620,
      "headline": "Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk",
      "id": 137303024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, November 03, 2025--Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.",
      "url": "https://finnhub.io/api/news?id=7857cf92c3127e42af7da3b65c2e174c5aaf06d5edd460d415b9bcfb0eea67d1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war",
    "summary": "Pfizer called Novo Nordisk’s last-minute bid to acquire Metsera “reckless and unprecedented”.",
    "url": "https://finnhub.io/api/news?id=1c6a1f11731684f086b8155e6bd9e814beac932451dc23407f70509ec709770a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762173883,
      "headline": "Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war",
      "id": 137303025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer called Novo Nordisk’s last-minute bid to acquire Metsera “reckless and unprecedented”.",
      "url": "https://finnhub.io/api/news?id=1c6a1f11731684f086b8155e6bd9e814beac932451dc23407f70509ec709770a"
    }
  },
  {
    "ts": null,
    "headline": "2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon",
    "summary": "These healthcare stocks are making strides in very important ways.",
    "url": "https://finnhub.io/api/news?id=59006f8b9732c67b65707dea79cabc39f01af7c2d8bd1fdc4fbbb58f86187d73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762173420,
      "headline": "2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon",
      "id": 137303026,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These healthcare stocks are making strides in very important ways.",
      "url": "https://finnhub.io/api/news?id=59006f8b9732c67b65707dea79cabc39f01af7c2d8bd1fdc4fbbb58f86187d73"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Gain Pre-Bell as Traders Eye Strong Start to November, Await More Earnings",
    "summary": "The benchmark US stock measures were tracking in the green before the opening bell Monday as traders",
    "url": "https://finnhub.io/api/news?id=4294550ef87f3e8b778009d821ce2d80c2703bd625ac9b431cc0e09a7fe05b60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762173241,
      "headline": "Stocks Gain Pre-Bell as Traders Eye Strong Start to November, Await More Earnings",
      "id": 137302194,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The benchmark US stock measures were tracking in the green before the opening bell Monday as traders",
      "url": "https://finnhub.io/api/news?id=4294550ef87f3e8b778009d821ce2d80c2703bd625ac9b431cc0e09a7fe05b60"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Sues Metsera, Novo Nordisk Over Alleged Breach of Merger Agreement",
    "summary": "Pfizer (PFE) said late Friday it filed a lawsuit against Metsera (MTSR), its board of directors, and",
    "url": "https://finnhub.io/api/news?id=aeec1d81ce9dabaf3ecdad4d9d6e04d4eb16ea79b6e806831bb656a040de76cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762168354,
      "headline": "Pfizer Sues Metsera, Novo Nordisk Over Alleged Breach of Merger Agreement",
      "id": 137303029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) said late Friday it filed a lawsuit against Metsera (MTSR), its board of directors, and",
      "url": "https://finnhub.io/api/news?id=aeec1d81ce9dabaf3ecdad4d9d6e04d4eb16ea79b6e806831bb656a040de76cb"
    }
  },
  {
    "ts": null,
    "headline": "Lung Cancer Antibody Drug Conjugates Research 2025: A $2 Billion Opportunity in 2030, Led by AstraZeneca, Daiichi Sankyo, Pfizer, and BMS Advancing Targeted Therapies Against HER2, TROP-2, and B7-H3",
    "summary": "Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration among major firms, and exploring personalized and combination therapies targeting specific genetic mutations and tumor antigens.Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"Lung Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price & Clinical Trials Insight 2030\" report has been added",
    "url": "https://finnhub.io/api/news?id=1f1e1fb19c6be28bbb10f7687e6f0f10e9cce587cde57c7867f84ac7c3814bb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762167960,
      "headline": "Lung Cancer Antibody Drug Conjugates Research 2025: A $2 Billion Opportunity in 2030, Led by AstraZeneca, Daiichi Sankyo, Pfizer, and BMS Advancing Targeted Therapies Against HER2, TROP-2, and B7-H3",
      "id": 137303030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration among major firms, and exploring personalized and combination therapies targeting specific genetic mutations and tumor antigens.Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"Lung Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price & Clinical Trials Insight 2030\" report has been added",
      "url": "https://finnhub.io/api/news?id=1f1e1fb19c6be28bbb10f7687e6f0f10e9cce587cde57c7867f84ac7c3814bb9"
    }
  },
  {
    "ts": null,
    "headline": "ESMO 2025: Celcuity gets first positive results for Pi3K inhibitor in PiK3CA wild-type HR+/HER2 breast cancer",
    "summary": "The design of the Phase 3 clinical trial and the agent’s profile position Celcuity well.",
    "url": "https://finnhub.io/api/news?id=82881bc7ca374e800205e76be5d5337b3f3895b4c3291022545280329fffde2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762165346,
      "headline": "ESMO 2025: Celcuity gets first positive results for Pi3K inhibitor in PiK3CA wild-type HR+/HER2 breast cancer",
      "id": 137303031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The design of the Phase 3 clinical trial and the agent’s profile position Celcuity well.",
      "url": "https://finnhub.io/api/news?id=82881bc7ca374e800205e76be5d5337b3f3895b4c3291022545280329fffde2a"
    }
  },
  {
    "ts": null,
    "headline": "United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb",
    "summary": "Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and",
    "url": "https://finnhub.io/api/news?id=2eadee4000155ed6b35aa4437da7c0e07a6decf3ae51676f37ee5680c157fe29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762164720,
      "headline": "United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb",
      "id": 137302169,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and",
      "url": "https://finnhub.io/api/news?id=2eadee4000155ed6b35aa4437da7c0e07a6decf3ae51676f37ee5680c157fe29"
    }
  },
  {
    "ts": null,
    "headline": "Meet the 7% Yield Dividend Stock That Could Soar in 2026",
    "summary": "This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term.",
    "url": "https://finnhub.io/api/news?id=37d385fba461814606fa8b1c1fca5c204d180a3c4b357fa75e0b3cf51b494ea1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762163160,
      "headline": "Meet the 7% Yield Dividend Stock That Could Soar in 2026",
      "id": 137303033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term.",
      "url": "https://finnhub.io/api/news?id=37d385fba461814606fa8b1c1fca5c204d180a3c4b357fa75e0b3cf51b494ea1"
    }
  },
  {
    "ts": null,
    "headline": "1 Incredible Reason to Buy Pfizer Stock (PFE) in November",
    "summary": "What would you say to a dividend yield of 7%?",
    "url": "https://finnhub.io/api/news?id=36df14a3b1c6e42541878f71e9393b54096d5e48df256febce8eddb9a3439504",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762160400,
      "headline": "1 Incredible Reason to Buy Pfizer Stock (PFE) in November",
      "id": 137303034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "What would you say to a dividend yield of 7%?",
      "url": "https://finnhub.io/api/news?id=36df14a3b1c6e42541878f71e9393b54096d5e48df256febce8eddb9a3439504"
    }
  },
  {
    "ts": null,
    "headline": "Tariffs, pricing, backroom deals — how pharma can navigate wildly shifting policies",
    "summary": "Gaming out new regulations and various potential outcomes will help keep companies on more solid footing.",
    "url": "https://finnhub.io/api/news?id=df3651281cdae837ea18be5cadb5a0dde59161366d41aa1fb11c9a70625ffda4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762156800,
      "headline": "Tariffs, pricing, backroom deals — how pharma can navigate wildly shifting policies",
      "id": 137303036,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Gaming out new regulations and various potential outcomes will help keep companies on more solid footing.",
      "url": "https://finnhub.io/api/news?id=df3651281cdae837ea18be5cadb5a0dde59161366d41aa1fb11c9a70625ffda4"
    }
  },
  {
    "ts": null,
    "headline": "McDonald’s Earnings, Tariff Update, Musk Pay Vote: What to Watch This Week",
    "summary": "Following President Trump's return from Asia, eyes are on whether an end to the government shutdown is in sight. Meanwhile, investors will dig into earnings from McDonald’s, Palantir and a host of other companies.",
    "url": "https://finnhub.io/api/news?id=ff8d2f32b639a1e96b557372561eb0ebd65fbd9227ae0f2adb2141eb5941029f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762155774,
      "headline": "McDonald’s Earnings, Tariff Update, Musk Pay Vote: What to Watch This Week",
      "id": 137302131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Following President Trump's return from Asia, eyes are on whether an end to the government shutdown is in sight. Meanwhile, investors will dig into earnings from McDonald’s, Palantir and a host of other companies.",
      "url": "https://finnhub.io/api/news?id=ff8d2f32b639a1e96b557372561eb0ebd65fbd9227ae0f2adb2141eb5941029f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Desperate Move",
    "summary": "Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.",
    "url": "https://finnhub.io/api/news?id=e00805c96aa4568bd2d7d1e10b14d04a28b64bf4547df75717d12193d6d04c07",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762137971,
      "headline": "Novo Nordisk: Desperate Move",
      "id": 137300713,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1128550847/image_1128550847.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.",
      "url": "https://finnhub.io/api/news?id=e00805c96aa4568bd2d7d1e10b14d04a28b64bf4547df75717d12193d6d04c07"
    }
  }
]